Search Results

Spruce Biosciences, Inc will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.

Spruce Biosciences, Inc. announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.

Spruce Biosciences, Inc. and HMNC Brain Health GmbH (“HMNC”), announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF1 receptor antagonist, with HMNC’s companion diagnostic, the proprietary Cortibon Genetic Selection Tool (“Cortibon”), for the treatment of MDD.

Spruce Biosciences, Inc. announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May.

Spruce Biosciences, Inc today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.

Spruce Biosciences, Inc. (Nasdaq: SPRB) presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024).